663 AdAPT-001, a First-in-class 2-in-1 TGF-beta Inhibitor Plus a Checkpoint Inhibitor: Updated Results from a Phase 2 Study in Solid Tumors
Regular and Young Investigator Award Abstracts（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined